ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DPH Dechra Pharmaceuticals Plc

3,866.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3,866.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Dechra Pharmaceuticals Share Discussion Threads

Showing 401 to 423 of 750 messages
Chat Pages: Latest  18  17  16  15  14  13  12  11  10  9  8  7  Older
DateSubjectAuthorDiscuss
09/5/2017
14:59
Joined your merry band. Looks like a breakout
volsung
09/5/2017
14:26
Yes, glad i added to my holding yesterday.
cfro
09/5/2017
13:14
Cheers, cfro; let's hope DPH does well for us.

We seem to be nudging further into breakout territory just now.

saucepan
03/5/2017
12:06
Bought in today. A thankyou goes to Saucepan and woodcutter for bringing the share to my attention.

Lovely quite board here which is refreshing to see. So many of the smaller companies boards are often busy with opposing views. I am getting increasingly disorientated and disillusioned with the more smaller, illiquid companies which havent performed well for me this year. My strategy now is one of moving away from these types into the likes of DPH with an emphasis on "quality".

cfro
02/5/2017
13:15
Keep the trolls away!
phillis
02/5/2017
13:12
Price is irrelevant. This is a great GARP share, and they tend to look expensive and have very quiet boards. Back to sleep.... zzzzz
dozey3
02/5/2017
11:42
Looks to me like a breakout is on the cards here from a lovely consolidation pattern. I am rather surprised this thread is so quiet - but then perhaps not; many private investors would regard a stock priced at £17 as "expensive".
saucepan
05/4/2017
18:23
a little pull back after some profit taking is probably in order. I shall continue to accumulate on any weakness.

woody

woodcutter
31/3/2017
22:20
Agreed, Woody, could be a very lucrative deal and one for the long term.
dozey3
31/3/2017
11:24
and a very interesting one for the future.........if the price falls a little I will add to my 3/5 year portfolio.
anley
31/3/2017
07:42
looks like a further quality deal/acquisition



woody

woodcutter
30/3/2017
09:05
added to my holding this morning. chart looks strong

woody

woodcutter
14/3/2017
10:25
Getting near your £17 ............ but why not think of £20 when they announce another record year.......but not just yet!
anley
02/3/2017
14:16
£17 !
phillis
27/2/2017
10:25
Aviva up thier holding before publication of results!! Think about that........

What a good set of results and more to play for by the management.

anley
27/2/2017
10:12
£16

Still with a head of steam!

phillis
10/2/2017
13:30
Whiskers and Fido rule ok.
steeplejack
27/1/2017
14:38
been accumulating a few times since it broke thro' 1400p

woody

woodcutter
17/1/2017
18:12
One reason why this company is a success is that the CEO has been able to create a team which is very able in extracting profits from all the acquisitions.

When a share goes up on a day like today then there is lot more good news to come over the coming year.

Well done the management ..........

anley
17/1/2017
07:35
Trading UpdateThe Board of Dechra issues the following unaudited Trading Update covering the half year reporting period (the Period) from 1 July to 31 December 2016.Highlights-- Reported Group revenue for the Period increased by approximately 34% at constant exchange rate (CER) (56% at actual exchange rate (AER)).-- Core Group revenue growth, excluding the benefit from acquisitions, was 7% at CER (AER 22%); growth in the core EU business was 6% at CER (AER 20%), and 10% (AER 31%) in North America.-- All acquisition integrations are progressing well with revenue contributions from Genera, Putney, Apex and Brovel being ahead of the Board's expectations.-- Approval by the FDA was achieved for the first major product from the Putney pipeline, a Companion Animal Product (CAP) generic antibiotic, Amoxi-clav.Ian Page, Chief Executive Officer, said:"Our underlying business and acquisitions have performed well, resulting in significant growth in the first half of the 2017 financial year. The Group pipeline has delivered new products and our global presence continues to increase. We remain confident in our strategy, our future prospects and our expectations for full year performance."
steeplejack
21/12/2016
17:24
Bought in to the story today as a one year+ holding............
anley
20/12/2016
08:40
Been buying quite a few recently

woody


free stock charts from uk.advfn.com

woodcutter
15/12/2016
10:57
perky today
phillis
Chat Pages: Latest  18  17  16  15  14  13  12  11  10  9  8  7  Older

Your Recent History

Delayed Upgrade Clock